Evidence map›Paper›PMID 41469157›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2026

Immunotheranostics in Solid Tumors: Longitudinal Tracking of Human IL13Rα2 CAR-T Cells In Vivo.

Hamid Reza Mirzaei, Samantha Lovibond, Leah Gajecki, Sarah Qureshy, Melina Kumpf, Pauline Jeanjean, Sang Gyu Lee, Winson Cai, Ileana Miranda, Audrey Mauguen and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Hamid Reza MirzaeiDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Samantha LovibondDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Leah GajeckiDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Sarah QureshyMolecular Pharmacology Program, Sloan Kettering Institute, New York, New York.
Melina KumpfDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Pauline JeanjeanDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Sang Gyu LeeDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Winson CaiMolecular Pharmacology Program, Sloan Kettering Institute, New York, New York.
Ileana MirandaLaboratory of Comparative Pathology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, New York, New York, and Rockefeller University, New York, New York.
Audrey MauguenDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Lukas M CarterDepartment of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York.
Heiko SchöderDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Darren R VeachDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
David A ScheinbergMolecular Pharmacology Program, Sloan Kettering Institute, New York, New York.
Simone KrebsDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York; sskrebs@mdanderson.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Tropism Enhanced Oncolytic Adenovirus for the Treatment of Brain TumorsP50CA127001 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Juan Fueyo · 2008 to 2026
$41.2M
Understanding and Mimicking TCR Recognition with Therapeutic Monoclonal Antibodies.R35CA241894 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI DAVID A SCHEINBERG · 2020 to 2026
$7.2M
Interrogating the in vivo pharmacokinetics of armored CARs with radiohapten captureR37CA262557 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Simone Krebs · 2021 to 2026
$3.4M
Targeting Drug-Resistant Castration Resistant Prostate Cancer via LIMK2R01CA237660 · NCI · PURDUE UNIVERSITY · PI RATLIFF, TIMOTHY L. · 2020 to 2024
$1.2M
IL13Ra2-targeted radioimmunotherapy for glioblastomaR21CA294042 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KREBS, SIMONE · 2025 to 2025
$432k
NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA127001NCI NIH HHS R01 CA237660NCI NIH HHS R21 CA294042NCI NIH HHS R35 CA241894NCI NIH HHS R37 CA262557
6 · The paper itself

Abstract

Chimeric antigen receptor (CAR)-T cell therapy has shown limited success in the treatment of solid tumors, reinforcing the need to elucidate the in vivo biodistribution of these engineered T cells. Here, we integrate the anti-DOTA huC825 reporter ("Thor") platform into newly developed human anti-interleukin-13 receptor α-2 (IL13Rα2)-single-cell fragment variable (scFv)-derived CAR-T cells and investigate its utility for mapping CAR-T cell distribution in a xenograft mouse model of melanoma.

Indexed as

Cell TrackingImmunotherapyInterleukin-13 Receptor alpha2 SubunitReceptors, Chimeric AntigenT-LymphocytesAnimalsCell Line, TumorHumansMiceTissue DistributionIL13RA2 protein, humanInterleukin-13 Receptor alpha2 SubunitReceptors, Chimeric AntigenCAR-T cellsIL13Rα2PET imagingreporter geneT-cell tracking

Identifiers

PMID41469157
PMCPMC13041584

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.